The Pharma Data

NOVEMBER 19, 2020

“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products.

Development 40

Development Bioavailability Production Drugs 40

The Pharma Data

DECEMBER 20, 2020

“We are encouraged by the data shown in these two studies of GPS in combination with checkpoint inhibitors and look forward to additional data from these studies,” stated Dragan Cicic, MD, Senior Vice President, Clinical Development of SELLAS. “We This press release contains forward-looking statements. Kenilworth, N.J.,

Life Science 52

Life Science Immune Response Trials Clinical Trials 52

The Pharma Data

NOVEMBER 30, 2020

It showcases our ability to advance strategically important candidates against specific disease targets through early development to become attractive partnering opportunities in parallel with the multi-target deals we have established. ” Abbreviations used: CGRP – calcitonin gene-related peptide. About Sosei Heptares.

Licensing 40

Licensing Licensing Production Development 40

The Pharma Data

JANUARY 4, 2021

“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products.

Licensing 40

Licensing Licensing Development Production 40

The Pharma Data

DECEMBER 8, 2020

We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture, and our bioinformatics leadership. United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model.

Drugs 40

Drugs FDA Approval Marketing Containment 40

The Pharma Data

DECEMBER 21, 2020

“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. Forward-looking statements.

Drugs 40

Drugs Protein Development Production 40

Pharmaceutical Technology

NOVEMBER 25, 2022

In many cases, pharma companies select a contract development and manufacturing organisation (CDMO) to develop products versus doing the work themselves for reasons related to cost, convenience, and capacity. In one specific case, Cambrex developed a PDF containing two APIs in suspension in an 80/20 ratio.

Manufacturing 130

Manufacturing Production Pharma Companies Development 130

The Pharma Data

FEBRUARY 25, 2021

. *8,9 Clinical studies demonstrated that TicoVac was well-tolerated with no unexpected adverse events or vaccine-related serious adverse events observed. DISCLOSURE NOTICE: The information contained in this release is as of February 23, 2021. This release contains forward?looking Available from: [link]. 2011;29(43):7307-19.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 18, 2021

We would like to thank the investigators and the clinical teams for their support and look forward to treating the first patients with this first Invir.IO generated oncolytic virus candidate to enter clinical development” said Dr. Maud Brandely, MD, PhD, Chief Medical Officer of Transgene. Transgene has an ongoing Invir.IO

Trials 40

Trials Antibody Engineer Clinical Trials 40

The Pharma Data

JANUARY 31, 2021

“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products.

Drugs 52

Drugs Protein In-Vitro Development 52

pharmaphorum

SEPTEMBER 3, 2020

Even now, with data to July for the US, IQVIA sees the dynamic market measure of ‘New to Brand’ depressed by between 6% and 40% compared to the equivalent period of 2019. And indeed, IQVIA’s data shows that across all countries, and non-COVID related therapy classes, the dynamic market in prescriptions fell, sometimes dramatically.

Doctors 84

Doctors Doctor Production Marketing 84

The Pharma Data

OCTOBER 26, 2020

Based on these promising findings, Transgene intends to continue the clinical development of TG4001 in a larger, controlled confirmatory study as we look to provide a better treatment option for this patient population,” added Dr. Maud Brandely, MD, PhD, Chief Medical Officer of Transgene. Transgene has an ongoing Invir.IO

Vaccination 52

Vaccination Vaccine Trials Containment 52

The Pharma Data

OCTOBER 28, 2020

Our results were once again driven by underlying growth of our 14 global brands across the five key business areas, which enabled us to generate strong margins and cash flow. Our 14 global brands, with reported revenue of JPY 595.9 Global Brand Highlights. billion in aggregate, delivered a 15.4%

Sales 40

Sales Production Engineer Development 40

The Pharma Data

JUNE 28, 2021

Israel and Taiwan as a monotherapy under the brand name Aliqopa for the treatment of adult patients with relapsed FL who have received at least two prior systemic therapies. These approvals are based on the results of a single-arm, multi-center, Phase II clinical trial (CHRONOS-1). for FL and MZL.

Trials 52

Trials Containment Branding Clinical Development 52

The Pharma Data

APRIL 11, 2021

obinutuzumab)-containing therapy (other previous treatment lines after rituximab were allowed) and either had a treatment-free interval of ?12 Israel and Taiwan under the brand name Aliqopa. Patients must have relapsed after the last rituximab-, rituximab biosimilars-, or anti-CD20 monoclonal antibody (e.g.,

HR 52

HR Trials Containment Development 52

XTalks

SEPTEMBER 14, 2020

“Vaccine Nationalism” Could Prove the Undoing of COVID-19 Containment. By the end of August, the World Health Organization (WHO) counted 33 vaccine candidates in some stage of clinical trial evaluation. Continuing trends suggest the worst may be over provided the outbreak is contained over the next few months.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92